Sees FY26 core operating income down low single digits vs. last year. “On December 19, 2025, Novartis (NVS) reached an agreement with the US government that aims to lower the price of innovative medicines in the US and support continued US investment in manufacturing, and research and development. The implications of that agreement are reflected in our 2026 guidance and in our 5-6% five- year sales CAGR guidance for 2025-2030. We will continue to monitor the longer-term implications as the agreement is implemented.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Novartis Posts Strong 2025 Results and Pipeline Wins as It Enters Major Patent-Expiry Year
- Novartis Files 2025 Annual and Nonfinancial Reports with U.S. SEC
- Avidity Biosciences announces expected record date for spin-off
- NVS Upcoming Earnings Report: What to Expect?
- The Week That Was, The Week Ahead: Macro and Markets, Feb. 1